Questions about adjuvant trastuzumab still remain.
Hind
Daniel
D
Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield S1 4DA, UK. d.hind@sheffield.ac.uk
Pilgrim
Hazel
H
Ward
Sue
S
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068878:Trastuzumab